Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2021; 13(9): 1069-1078
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1069
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1069
Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
Ezequiel Ridruejo, Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno “CEMIC”, Ciudad Autónoma de Buenos Aires C1425AS, Unspecified, Argentina
Matías Javier Pereson, Federico Alejandro Di Lello, Facultad de Farmacia y Bioquímica, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires 1113, Argentina
Diego M Flichman, Instituto de Investigaciones Biomédicas en Retrovirus y Síndrome de Inmunodeficiencia Adquirida (INBIRS), Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires 1113, Argentina
Author contributions: Ridruejo E and Di Lello FA designed and wrote the manuscript; Pereson MJ and Flichman DM wrote the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflicting interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Federico Alejandro Di Lello, PhD, Research Scientist, Teacher, Facultad de Farmacia y Bioquímica, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Universidad de Buenos Aires, Junin 9564 Piso, RA-1113 Buenos Aires, Ciudad Autónoma de Buenos Aires 1113, Argentina. fadilello@ffyb.uba.ar
Received: February 22, 2021
Peer-review started: February 22, 2021
First decision: May 3, 2021
Revised: May 12, 2021
Accepted: August 10, 2021
Article in press: August 10, 2021
Published online: September 27, 2021
Processing time: 211 Days and 9.6 Hours
Peer-review started: February 22, 2021
First decision: May 3, 2021
Revised: May 12, 2021
Accepted: August 10, 2021
Article in press: August 10, 2021
Published online: September 27, 2021
Processing time: 211 Days and 9.6 Hours
Core Tip
Core Tip: The presence of resistance-associated substitutions (RAS) to hepatitis C virus (HCV) treatment is a frequent event. Direct-acting antiviral (DAA) treatment repre